EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Biopotency and surrogate assays to validate the immunomodulatory potency of extracellular vesicles derived from mesenchymal stem/stromal cells for the treatment of experimental autoimmune uveitis

Gagandeep Kaur, Eun-Hye Bae, Yu Zhang, Nicole Ciacciofera, Kyung Min Jung, Heather Barreda, Carol Paleti, Joo Youn Oh, Ryang Hwa Lee iD

Journal of Extracellular Vesicles · 2024-08 · 13 (8)

DOI: 10.1002/jev2.12497 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Extracellular Vesicles, online erschienen am 14.08.2024. Verfasst von Gagandeep Kaur und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cell Biology and Genetics, Institute for Regenerative Medicine, Texas A&M University School of Medicine, College Station, Texas, USA. Hauptthemen laut MEDLINE: Extracellular Vesicles, Mesenchymal Stem Cells, Uveitis, Transforming Growth Factor beta1. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIDCR NIH HHS, NEI NIH HHS, National Eye Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Extracellular vesicles (EVs) derived from mesenchymal stem/stromal cells (MSCs) have been recognized as promising cytotherapeutics due to their demonstrated immunomodulatory effects in various preclinical models. The immunomodulatory capabilities of EVs stem from the proteins and genetic materials they carry from parent cells, but the cargo contents of EVs are significantly influenced by MSC tissues and donors, cellular age and culture conditions, resulting in functional variations. However, there are no surrogate assays available to validate the immunomodulatory potency of MSC‐EVs before in vivo administration. In previous work, we discovered that microcarrier culture conditions enhance the immunomodulatory function of MSC‐EVs, as well as the levels of immunosuppressive molecules such as TGF‐β1 and let‐7b in MSC‐EVs. Building on these findings, we investigated whether TGF‐β1 levels in MSC‐EVs could serve as a surrogate biomarker for predicting their potency in vivo. Our studies revealed a strong correlation between TGF‐β1 and let‐7b levels in MSC‐EVs, as well as their capacity to suppress IFN‐γ secretion in stimulated splenocytes, establishing biopotency and surrogate assays for MSC‐EVs. Subsequently, we validated MSC‐EVs generated from monolayer cultures (ML‐EVs) or microcarrier cultures (MC‐EVs) using murine models of experimental autoimmune uveoretinitis (EAU) and additional in vitro assays reflecting the Mode of Action of MSC‐EVs in vivo . Our findings demonstrated that MC‐EVs carrying high levels of TGF‐β1 exhibited greater efficacy than ML‐EVs in halting disease progression in mice with EAU as well as inducing apoptosis and inhibiting the chemotaxis of retina‐reactive T cells. Additionally, MSC‐EVs suppressed the MAPK/ERK pathway in activated T cells, with treatment using TGF‐β1 or let‐7b showing similar effects on the MAPK/ERK pathway. Collectively, our data suggest that MSC‐EVs directly inhibit the infiltration of retina‐reactive T cells toward the eyes, thereby halting the disease progression in EAU mice, and their immunomodulatory potency in vivo can be predicted by their TGF‐β1 levels.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Extracellular VesiclesMesenchymal Stem CellsUveitisTransforming Growth Factor beta1MicroRNAsAnimalsMiceAutoimmune DiseasesDisease Models, AnimalImmunomodulationMice, Inbred C57BLHumansFemale

Stichwörter der Autor:innen

EVsMSCMSC‐EVsTGF‐β1autoimmune diseaseautoreactive T cellsbiopotency assayexosomesfunction assaylet‐7bmicrocarrier culturesurrogate assay

Substanzen

Transforming Growth Factor beta1MicroRNAsmirnlet7 microRNA, mouse

Autor:innen und Institutionen

  • Department of Cell Biology and Genetics, Institute for Regenerative Medicine, Texas A&M University School of Medicine, College Station, Texas, USA.
  • Department of Ophthalmology, Seoul National University College of Medicine, Seoul, South Korea.

ORCID-Profile: Ryang Hwa Lee

Förderung

  • NIDCR NIH HHS
  • NEI NIH HHS
  • National Eye Institute
  • National Institute of Dental and Craniofacial Research

Zitieren

APA

Kaur, G., Bae, E. H., Zhang, Y., Ciacciofera, N., Jung, K. M., Barreda, H., Paleti, C., Oh, J. Y., & Lee, R. H. (2024). Biopotency and surrogate assays to validate the immunomodulatory potency of extracellular vesicles derived from mesenchymal stem/stromal cells for the treatment of experimental autoimmune uveitis. Journal of Extracellular Vesicles, 13(8). https://doi.org/10.1002/jev2.12497

Vancouver

Kaur G, Bae EH, Zhang Y, Ciacciofera N, Jung KM, Barreda H, et al. Biopotency and surrogate assays to validate the immunomodulatory potency of extracellular vesicles derived from mesenchymal stem/stromal cells for the treatment of experimental autoimmune uveitis. Journal of Extracellular Vesicles. 2024;13(8). doi:10.1002/jev2.12497

BibTeX
@article{Kaur2024,
  author = {Kaur, Gagandeep and Bae, Eun-Hye and Zhang, Yu and Ciacciofera, Nicole and Jung, Kyung Min and Barreda, Heather and Paleti, Carol and Oh, Joo Youn and Lee, Ryang Hwa},
  title = {Biopotency and surrogate assays to validate the immunomodulatory potency of extracellular vesicles derived from mesenchymal stem/stromal cells for the treatment of experimental autoimmune uveitis},
  journal = {Journal of Extracellular Vesicles},
  year = {2024},
  volume = {13},
  number = {8},
  doi = {10.1002/jev2.12497}
}
Kostenlos starten →